How we treat Waldenström's macroglobululinemia

Haematologica

Volumn 90, Issue 1, 2005, Pages 117-125

  Dimopoulos, Meletios A ^a,e   Merlini, Giampaolo ^b   Leblond, Veronique ^c   Anagnostopoulos, Athanasios ^a   Alexanian, Raymond ^d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PAVIA   (Italy)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NONE   (Greece)

Author keywords

Chlorambucil; Cladribine; Fludarabine; Practice guidelines; Rituximab; Waldenstr m's macroglobulinemia

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; MELPHALAN; MONOCLONAL ANTIBODY; NITROSOUREA; NUCLEOSIDE ANALOG; PARAPROTEIN; PLASMA PROTEIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCA ALKALOID;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER SURVIVAL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESISTANCE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NEUROPATHY; PLASMAPHERESIS; PRACTICE GUIDELINE; PUBLICATION; REVIEW; SPLENECTOMY; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; VISCEROMEGALY; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; COMBINED MODALITY THERAPY; HUMANS; PLASMAPHERESIS; SPLENECTOMY; STEM CELL TRANSPLANTATION; WALDENSTROM MACROGLOBULINEMIA;

EID: 13244259542     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Waldenström J. Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia-A new syndrome¿ Acta Med Scand 1944;117: 216-22.
2. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, Mc Master ML, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003;30:110-5.
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17: 3835-49.
5. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guizo F, Sanchez ML, et al. Immunophenotypic analysis of Waldenström's macroglobulinemia. Semin Oncol 2003;30:187-95.
6. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18: 214-26.
7. Kyle RA, Therneau TM, Raikumar SV, Offord JR, Larson DR, Plevak MF, et al. Long-term follow-up of IgM monoclonal gammopathy of undertermined significance. Semin Oncol 2003;30: 169-71.
8. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos MA. Asymptomatic Waldenström's macroglobulinemia. Semin Oncol 2003;30:206-10.
9. Cesana C, Miqueleiz S, Bernuzzi P, Tresoldi E, Rossi V, D'Avanzo G, et al. Smouldering Waldenström's macroglobulinemia: factors predicting evolution to symptomatic disease. Semin Oncol 2003;30:231-6.
10. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003;30:116-20.
11. Buskard NA, Galton DAG, Godman JM. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. Com Med Ass J 1977;117:135-7.
12. Clark WF, Rock GA, Buskard N, Shumak KH, Leblond P, Anderson D, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999;131:453-62.
13. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737-42.
14. Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hidderman W, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle cell lymphoma. J Clin Oncol 1999;17:546-53.
15. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US Intergroup Trial (SWOG 5903). Semin Oncol 2003;30:220-5.
16. Dimopoulos MA. Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, et al. Primary therapy of Waldenström' macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12: 2694-8.
17. Delannoy A, Van de Neste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenström's macroglobulinemia. Br J Haematol 1999;104:933.
18. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. Firstline treatment of Waldenström's disease with cladribine. Ann Hematol 1997;74:7-10.
19. Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Hellman A. 2-chlorodeoxyadenosine treatment of Waldenström's macrolgobulinemia-the analysis of own experience and the review of literature. Med Sci Monit 2000;6:740-5.
20. Hampshire A, Saven A. Update of bolus administration of cladribine in the treatment of Waldenström's macroglobulinemia. Blood 2003; 102 suppl 1:402[abstract].
21. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chloredeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol 2003;30:243-7.
22. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 1993;95:49-52.
23. Zinzani PL, Gherlinzoni F, Bendandi M, Zaccaria A, Aitini E, Salvucci M, et al. Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol 1995;54:120-3.
24. Leblond V, Ben-Ohtman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, et al. Activity of fludarabine in previously treated Waldeström's macroglobulinemia: a report of 71 cases. Group Cooperatif Macroglobulinemie. J Clin Oncol 1998;16:2060-4.
25. Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640-4.
26. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995;6: 49-52.
27. Betticher DC, Hsu Schmitz SF, Ratschiller D, von Rohr A, Egger T, Pugin P, et al. Cladribine (2-CDA) given as subcutaneous bolus injection is active in pretreated Waldenström's macroglobulinemia. Swiss Group for Clinical Cancer Research. Br J Haematol 1997; 99:358-63.
28. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525-7.
29. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Goldstone A, Sweetenham JW, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-24.
30. Treon SP, Agus DB, Link B, Rodriguez G, Molina A, Lacy MQ et al. CD20 Directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macrolglobulinemia. J Immunother 2001;24:272-9.
31. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-33.
32. Dimopoulos MA, Zervas K, Zomas A, Anagnostopoulos A, Kyrtsonis MC, Anagnostopoulos N, et al. Treatment of Waldenström's macroglobulinemia with rituximab: prognostic factors for response and progression. Blood 2003; 102 Suppl 1:448[abstract].
33. Gertz MA, Rue M, Blood E. Rituximab for Waldenström's macroglobulinemia (E3A98): an ECOG phase II pilot study for untreated or previously treated patients. Blood 2003; 102 Suppl 1:148 [abstract].
34. Treon SP, Emmanouilides C, Kimby E, Abigail K, Preffer F, Branagan AR, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol (in press).
35. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole D, et al. The initial "flare" of IgM level after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Blood 2003;102 Suppl 1:448 [abstract].
36. Treon SP, Wasi P, Emmanouilides C, Frankel SR, Kimby E, Lister A, et al. Combination therapy with rituximab and fludarabine is highly active in Waldenström's macroglobulinemia. Blood 2002;100 Suppl 1:211 [abstract].
37. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinemia. Br J Haematol 1999;105:993-6.
38. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström's macroglobulinemia. Bone Marrow Transplant 2001;27: 1027-9.
39. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Colombat P, Milpied N, et al. Transplantation in Waldenström's macroglobulinemia: the French experience. Sem Oncol 2003;30:291-6.
40. Munshi NC, Barlogie B. Role of high-dose therapy with autologous hematopoietic stem cell support in Waldenström's macroglobulinemia. Semin Oncol 2003;30:282-5.
41. Seyfarth B, Sonnen R, Zeis M, Schoch R, Schmitz N, Dreger P. Follow-up of autologous stem cell transplantation for treatment of Waldenström's macroglobulinemia. Blood 2003; 102 Suppl 1:987[abstract].
42. Anagnostopoulos A, Giralt S. Autologous and allogeneic stem cel transplantation in Waldenström's macroglobulinemia: review of the literature and future directions. Semin Oncol 2003;30:286-0.
43. Maloney DG, Sandmaier BM, Maris M, Niederwieser D, Agura E, Maziar RT, et al. Allogeneic hematopoietic cell transplantation for refractory Waldenström's macroglobulinemia-replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 2003; 102 Suppl 2:472b [abstract].
44. Dimopoulos MA, Tsatalas C, Zomas A, Hamilos G, Panayiotidis P, Margaritis D, et al. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide of with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30:265-9.
45. Mitsiades C, Mitsiades N, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. The proteasome inhibitors bortezomib (PS-341) is active against Waldenström's macroglobulinemia. Blood 2003;102 Suppl 1: 181[abstract].
46. Goy AG, Younes A, Mc Langhlin P, Pro B, Romaguera JE, Hagemeister F, et al. A phase II study of proteasome inhibitor bortezomib in relapsed or refractory indolent or aggressive B-cell non-Hodgkin's lymphoma. Hematol J 2004; 5 suppl 2:5204-5.
47. Humphrey JS, Lockard C. Durable complete remission of macroglobulinemia after splenectomy. Am J Hematol 1995;48:262-6.
48. Cavanna L, Berté R, Lazzaro A, Valissa D, Moroni CF, Civardi G. Advanced Waldenström's macrolgobulinemia: a case of possible cure after systemic chemotherapy, splenic radiation and splenectomy. Acta Haematol 2002; 108:97-101.
49. Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel S, et al. Treatment recommendations in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003;30:121-6.
50. Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, et al. Survival and prognostic factors after initiation of treatment in Waldenström's macroglobulinemia. Ann Oncol 2003;14:1299-305.